Found: 73
Select item for more details and to access through your institution.
Shortages of Essential Generic Drugs with Limited Competition.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
- Published in:
- JAMA Internal Medicine, 2024, v. 184, n. 1, p. 63, doi. 10.1001/jamainternmed.2023.6293
- By:
- Publication type:
- Article
Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021.
- Published in:
- JAMA Internal Medicine, 2023, v. 183, n. 3, p. 275, doi. 10.1001/jamainternmed.2022.6299
- By:
- Publication type:
- Article
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?
- Published in:
- 2021
- By:
- Publication type:
- journal article
Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States.
- Published in:
- 2021
- By:
- Publication type:
- journal article
US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Use of "Doctor" Badges for Physician Role Identification During Clinical Training.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 4, p. 409, doi. 10.1001/jamadermatol.2023.6236
- By:
- Publication type:
- Article
Market dynamics of authorized generics in Medicaid from 2014 to 2020.
- Published in:
- Health Services Research, 2023, v. 58, n. 4, p. 953, doi. 10.1111/1475-6773.14145
- By:
- Publication type:
- Article
Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty
- Published in:
- PLoS ONE, 2013, v. 8, n. 5, p. 1, doi. 10.1371/journal.pone.0062709
- By:
- Publication type:
- Article
State Spending Targets for Prescription Drugs.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.
- Published in:
- JAMA Health Forum, 2024, v. 5, n. 4, p. e240302, doi. 10.1001/jamahealthforum.2024.0302
- By:
- Publication type:
- Article
Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
- Published in:
- JAMA Health Forum, 2024, v. 5, n. 3, p. e235429, doi. 10.1001/jamahealthforum.2023.5429
- By:
- Publication type:
- Article
Association of Perceived Role Misidentification With Use of Role Identity Badges Among Resident Physicians.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 7, p. e2224236, doi. 10.1001/jamanetworkopen.2022.24236
- By:
- Publication type:
- Article
Association of Perceived Role Misidentification With Use of Role Identity Badges Among Resident Physicians.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 7, p. 1, doi. 10.1001/jamanetworkopen.2022.24236
- By:
- Publication type:
- Article
Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 11, p. e2135362, doi. 10.1001/jamanetworkopen.2021.35362
- By:
- Publication type:
- Article
Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules.
- Published in:
- 2021
- By:
- Publication type:
- Opinion
Misaligned Pharmacy Incentives in Value-Based Care.
- Published in:
- 2024
- By:
- Publication type:
- Opinion
State Coverage and Reimbursement of Antiobesity Medications in Medicaid.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 14, p. 1230, doi. 10.1001/jama.2024.3073
- By:
- Publication type:
- Article
Spending on Targeted Therapies for Duchenne Muscular Dystrophy.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, p. 1151, doi. 10.1001/jama.2024.2776
- By:
- Publication type:
- Article
Direct-to-Consumer Drug Company Pharmacies.
- Published in:
- JAMA: Journal of the American Medical Association, 2024, v. 331, n. 12, p. 1003, doi. 10.1001/jama.2024.2911
- By:
- Publication type:
- Article
The Inflation Reduction Act and Access to High-Cost Cardiovascular Therapies.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 17, p. 1619, doi. 10.1001/jama.2023.19129
- By:
- Publication type:
- Article
Gauging the Value of Top-Selling Drugs in Medicare—Reply.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 7, p. 665, doi. 10.1001/jama.2023.10961
- By:
- Publication type:
- Article
Congress' Misguided Plan to Ban QALYs.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 24, p. 2125, doi. 10.1001/jama.2023.8695
- By:
- Publication type:
- Article
Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 18, p. 1607, doi. 10.1001/jama.2023.3079
- By:
- Publication type:
- Article
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 15, p. 1283, doi. 10.1001/jama.2023.4034
- By:
- Publication type:
- Article
Medicare Negotiation's Drug Reformulation Problem.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 6, p. 833, doi. 10.7326/M23-3212
- By:
- Publication type:
- Article
Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022: An Interrupted Time-Series Analysis.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 11, p. 1508, doi. 10.7326/M23-1609
- By:
- Publication type:
- Article
Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.
- Published in:
- 2022
- By:
- Publication type:
- research
Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2024, v. 33, n. 10, p. 1, doi. 10.1002/pds.70009
- By:
- Publication type:
- Article
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 11, p. e2343285, doi. 10.1001/jamanetworkopen.2023.43285
- By:
- Publication type:
- Article
The Rise and Fall of the Insulin Pricing Bubble.
- Published in:
- 2023
- By:
- Publication type:
- Opinion
Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 4, p. e237467, doi. 10.1001/jamanetworkopen.2023.7467
- By:
- Publication type:
- Article
Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2024, v. 81, n. 1, p. 85, doi. 10.1001/jamaneurol.2023.4514
- By:
- Publication type:
- Article
Lifetime Risk and Age at Diagnosis of Symptomatic Knee Osteoarthritis in the US.
- Published in:
- Arthritis Care & Research, 2013, v. 65, n. 5, p. 703, doi. 10.1002/acr.21898
- By:
- Publication type:
- Article
Addressing High Drug Prices by Reforming Pharmacy Benefit Managers.
- Published in:
- Journal of Law, Medicine & Ethics, 2023, v. 51, p. 46, doi. 10.1017/jme.2024.23
- By:
- Publication type:
- Article
Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
- Published in:
- Journal of Law, Medicine & Ethics, 2024, v. 52, n. 1, p. 188, doi. 10.1017/jme.2024.56
- By:
- Publication type:
- Article
Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European Union.
- Published in:
- Journal of Law, Medicine & Ethics, 2023, v. 51, n. 1, p. 213, doi. 10.1017/jme.2023.58
- By:
- Publication type:
- Article
Reply to Boucher et al.
- Published in:
- Clinical Infectious Diseases, 2021, v. 72, n. 9, p. e422, doi. 10.1093/cid/ciaa095
- By:
- Publication type:
- Article
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 7, p. 1671, doi. 10.1093/cid/ciz1039
- By:
- Publication type:
- Article
Patient Out‐of‐Pocket Costs Following the Availability of Biosimilar Versions of Infliximab.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 113, n. 1, p. 90, doi. 10.1002/cpt.2763
- By:
- Publication type:
- Article
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012–2018.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 2, p. 367, doi. 10.1002/cpt.1983
- By:
- Publication type:
- Article
Estimating Rebates and Other Discounts Received by Medicare Part D.
- Published in:
- JAMA Health Forum, 2021, v. 2, n. 6, p. 1, doi. 10.1001/jamahealthforum.2021.0626
- By:
- Publication type:
- Article